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Abstract
A 2-year-old male domestic shorthair cat was presented for a progressive history of
abnormal posture, behavior, and mentation. Menace response was absent bilaterally,
and generalized tremors were identified on neurological examination. A neuroana-
tomical diagnosis of diffuse brain dysfunction was made. A neurodegenerative disor-
der was suspected. Magnetic resonance imaging findings further supported the
clinical suspicion. Whole-genome sequencing of the affected cat with filtering of vari-
ants against a database of unaffected cats was performed. Candidate variants were
confirmed by Sanger sequencing followed by genotyping of a control population.
Two homozygous private (unique to individual or families and therefore absent from
the breed-matched controlled population) protein-changing variants in the major
facilitator superfamily domain 8 (MFSD8) gene, a known candidate gene for neuronal
ceroid lipofuscinosis type 7 (CLN7), were identified. The affected cat was homozy-
gous for the alternative allele at both variants. This is the first report of a pathogenic
alteration of the MFSD8 gene in a cat strongly suspected to have CLN7.
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1 | INTRODUCTION
The neuronal ceroid lipofucinoses (NCLs), also collectively called
Batten disease, are a heterogeneous group of inherited, progressive,
neurodegenerative disorders. In humans, 14 genetically distinct forms
of NCL have been identified, and all are characterized by abnormal
intralysosomal accumulation of autofluorescent material, which leads
to progressive degeneration of cortical and cerebellar structures with
secondary fiber tract atrophy. Each gene is called CLN (ceroid
lipofuscinosis, neuronal) and given a different number designation as
its subtype. The NCLs are among the most prevalent of the childhood
neurodegenerative diseases.1 Despite genetic heterogeneity, the clini-
cal phenotype often is similar and includes progressive loss of motor
ability, cognitive deterioration, visual failure, and epileptic seizures.2
Although they are always fatal, death can occur early or later in life.
The magnetic resonance imaging (MRI) features are cerebral and cere-
bellar atrophy, mild hyperintensity of the cerebral white matter on
T2-weighted images (T2WI), thinning of the cortex, and hypointensity
of the thalami on T2WI, and their appearance correlates with the
Abbreviations: ADC, apparent diffusion coefficient; CCMD, macular dystrophy with central
cone involvement; MFSD8, major facilitator superfamily domain 8; MRI, magnetic resonance
imaging; MRS, magnetic resonance spectroscopy; NCBI, National Center for Biotechnology
Information; NCL, neuronal ceroid lipofuscinosis; PCR, polymerase chain reaction; T2WI,
T2-weighted image.
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duration of the disease.3,4 The NCLs feature an autosomal recessive
mode of inheritance except CLN4, which has an autosomal dominant
pattern.1 Different sequence variants can occur in a given gene and
present with different clinical phenotypes. The CLN7 form has a late
infantile onset and is caused by genetic variants in the MFSD8 gene
encoding a lysosomal protein termed major facilitator superfamily
domain 8 (MFSD8). The MFSD8 protein is an atypical solute carrier
protein whose physiological substrate is not known.1
The NCLs also have been reported in dogs but only rarely in cats.5-12
So far, causative genetic variants in dogs are known for CLN1, 2, 5, 6, 7,
8, 10, and 12,13-22 whereas none have been reported in cats. Clinically,
for a dog to be considered a candidate for the disorder, progressive neu-
rological signs including at least 4 of the following must be present: loss
of vision, behavioral changes (eg, development of aggressive behavior),
loss of learned behaviors, tremors, cerebellar ataxia, cognitive and motor
decline, sleep disturbance, and seizures.23 The NCLs are invariably fatal,
and the severity of the clinical signs often leads to euthanasia. Although
not pathognomonic for the disease, the identification on MRI of cerebral
and cerebellar atrophy with widened cerebral sulci, cerebellar folia, and
increased volume in the ventricular system23,24 further increases the
antemortem suspicion. Similar clinical and imaging findings have been
reported in cats.5-12 Because the clinical signs and the imaging findings
can overlap with other lysosomal storage diseases, identification of accu-
mulation of autofluorescent ceroid storage material in neurological tis-
sues is required for confirmation.23 Advances in genetics have permitted
antemortem screening for genetic variants in known NCL candidate
genes in suspected cases and have allowed for confirmation of NCL by
demonstration that the disease results from a known NCL pathogenic
sequence variant.25 In this report, we describe the clinical, imaging, and
genetic findings in a cat with suspected NCL diagnosed antemortem.
2 | MATERIALS AND METHODS
2.1 | Animal selection/phenotyping
All animal experiments were performed according to local regulations.
The cat in our study was privately owned and examined with the consent
of the owner. The Cantonal Committee for Animal Experiments approved
the collection of blood samples (Canton of Bern; permit 75/16).
We selected 1 affected and 141 unaffected cats for inclusion in this
study. The probandwas a 2-year-old male domestic shorthair cat displaying
aggression toward the owner and its housemate. It had always displayed an
ataxic gait in all 4 limbs, but the gait disturbance became more evident
around 6 months of age. A progressive crouched posture, loss of learned
behavior, and abnormal mentation (disorientation) also were reported.
Physical and neurological evaluation identified dull mentation, abnormal
cranial nerves examination with absent menace bilaterally, normal pupillary
light and dazzle reflexes, normal proprioception and segmental spinal
reflexes in all 4 limbs. Generalized tremors alsowere observed. A neuroana-
tomic diagnosis of brain dysfunction with a diffuse disorder affecting the
forebrain and cerebellum was made by a board-certified veterinary
neurologist. In light of the age of the cat and the progressive nature of the
clinical signs, a neurodegenerative disorder was suspected. A CBC and
serum biochemistry findings were normal, including microscopic assess-
ment of thewhite blood cells. Urinalysis alsowas normal. Urine oligosaccha-
ride and mucopolysaccharide concentrations testing were normal when
compared to an age-matched healthy control cat. Magnetic resonance
imaging of the brain identified marked brain atrophy with decreased gray
andwhitematter demarcation, thinning of the corpus callosum,mildwiden-
ing of the cerebellar sulci, mild tomoderate dilatation of the lateral and third
ventricles, mild widening of the cerebellar sulci, and hyperostosis of the
frontal, parietal, temporal, and occipital bones including the tentorium
cerebelli (Figure 1). This imaging phenotype is similar than previously
reported.12 Cerebrospinal fluid analysis was normal. Abdominal ultrasound
examinationwas normal.
Unaffected control cats of various breeds were obtained from a
pool of data from cats donated to the Vetsuisse Biobank. The related-
ness among these cats was unknown. Genomic DNA was isolated from
ethylenediaminetetraacetate blood with the Maxwell RSC Whole Blood
Kit using a Maxwell RSC instrument (Promega).
2.2 | Whole-genome sequencing of an affected
domestic shorthair cat
An Illumina TruSeq polymerase chain reaction (PCR)-free DNA library
with 350 base pair (bp) insert size was prepared from the affected cat
(K548). We collected 286 million 2 × 150 bp paired-end reads on a
NovaSeq 6000 instrument (30 × coverage). Mapping and alignment
were performed as previously described.26 The sequence data were
deposited under study accession PRJEB7401 and sample accession
SAMEA5885930 at the European Nucleotide Archive.
2.3 | Variant calling
A variant filtering was performed.26 To predict the functional effects
of the called variants, SnpEFF27 software together with National Cen-
ter for Biotechnology Information (NCBI) annotation release 105 for
felCat9 was used. For variant filtering, we used 38 control genomes,
which were produced during other projects of our group.
TABLE 1 Results of variant filtering in the affected and
38 unaffected cats
Filtering step
Homozygous
variants
Heterozygous
variants
Privatea variants 45 586 109 336
Protein-changing
private variants
167 414
Privatea variants in
known NCL candidate genes
2 0
aPrivate: Unique to individual or families and therefore absent from the
breed-matched controlled population.
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2.4 | Gene analysis
We used the Felis catus 9.0 reference genome assembly for all analyses.
Numbering within the felineMFSD8 gene corresponds to the NCBI RefSeq
accessions XM_019828986.2 (mRNA) and XP_019684545.1 (protein).
2.5 | Sanger sequencing
The MFSD8:c.19G>C variant and the MFSD8:c780delT were
genotyped by direct Sanger sequencing of PCR amplicons. A
600 bp PCR product was amplified from genomic DNA using
AmpliTaqGold360Mastermix (Life Technologies) together with
primers 50-AGC CCT GTG TCT GTT CTG TG-30 (Primer F) and 50-
AGG CAT ACG TTT TGT CAT GAT G-30 (Primer R) for the frame-
shift variant and primers 50-GAA AGC TAG GAC ACA GGG CC-30
(Primer F) and 50-CAC GTC TCC CAG AAG TTC CG-30 (Primer R)
for the missense variant. After treatment with exonuclease I and
alkaline phosphatase, amplicons were sequenced on an ABI 3730
DNA Analyzer (Life Technologies). Sanger sequences were ana-
lyzed using the Sequencher 5.1 software (GeneCodes).
TABLE 2 Genotype phenotype association of theMFSD8:
c.19G>C and c.780delT variants
c.19G>C c.780delT
G/G C/C T/T del/del
Case … 1 … 1
Controls 141 … 141 …
F IGURE 1 MRI of the brain in the affected cat. A, Transverse T2-weighted image (T2WI) at the level of the thalamus. Diffuse cerebral
atrophy (asterisk) with widened cerebral sulci and increased cerebrospinal fluid signal within the subarachnoid space (arrow). Marked hyperostosis
is also identified (arrowhead). B, Transverse proton density-weighted image at the same level than (A) highlights the poor demarcation between
gray and white matter (asterisk). C, Midsagittal T2WI showing the diffuse increased signal intensity within the subarachnoid space secondary to
the diffuse brain atrophy. Diffuse marked hyperostosis is also seen affecting the tentorium cerebelli and occipital bone (arrowhead). The corpus
callosum is thin (asterisk), and there is mild widening of the cerebellar sulci
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3 | RESULTS
3.1 | Genetic analysis
We sequenced the genome of the affected cat and searched for
homozygous and heterozygous variants that were not present in
38 control cats of different breeds (Table 1). We prioritized variants
that were predicted to change the amino acid sequence of 1 of the
known NCL candidate genes (Table S1).
We identified 2 homozygous Private (unique to individual or families
and therefore absent from the breed-matched controlled population)
protein-changing variants in known NCL candidate genes. Both variants
were located in the MFSD8 gene. A missense variant was located in the
MFSD8 gene and was designated ChrB1:98899302G>C (Felis_catus_9.0
assembly). This variant, XM_019828986.2:c.19G>C, is predicted to result
in the amino acid change XP_019684545.1:p.(Asp7His). The second vari-
ant was a frameshift variant, also located in theMFSD8 gene. It was desig-
nated as XM_019828986.2:c.780delT or XP_019684545.1:p.
(Gln262Lysfs*33). The frameshift truncates 253 codons (49%) of the wild-
type sequence. The wild-type MFSD8 protein consists of 514 amino acids
including 12 transmembrane domains required for anchoring the mature
protein in the lysosomal membrane. Themutant transcript lacks the coding
information for the last 6 transmembrane domains. We confirmed the
presence of bothMFSD8 variants by Sanger sequencing. The affected cat
was homozygous for the alternative allele at both variants.
We also genotyped 141 control cats (Table S2). All control cats
were homozygous for the wild-type allele at both variants (Table 2)
resulting in an allele frequency of 0%.
4 | DISCUSSION
We identified a missense and a frameshift variant in the MFSD8 gene
in a cat with clinical and imaging phenotype highly compatible with
NCL. The clinical, imaging, and genetic findings together strongly sup-
port the diagnosis of CLN7.
The clinical features of 8 cats with NCL confirmed by histopathol-
ogy have been reported since 1974.5-12 Domestic shorthair (7/9) cats
and Siamese (2/9) are the 2 reported breeds. Most cats were young
adults by the time they were assessed (1-2 years old) although earlier
clinical signs were reported at a few months of age. In 9 cats (includ-
ing ours), the most commonly reported clinical signs were vision loss
(6/9), seizures (5/9), abnormal mentation (4/9), abnormal behavior
(4/9), abnormal gait (4/9), hyperesthesia (3/9), tremors (3/9), and
myoclonus (2/9). Evidence of progressive forebrain signs in a young
adult cat therefore should raise the suspicion for NCL.
The MRI characteristics of 1 cat with confirmed NCL have been
reported.12 The findings included generalized and symmetrical brain cor-
tical atrophy with secondary dilatation of the ventricular system and
intracranial subarachnoid space as observed in our cat. Reduction in size
of the corpus callosum also was reported. These findings are similar to
those in affected dogs and humans.3,4,23 Furthermore, in humans,
longitudinal MRI and magnetic resonance spectroscopy (MRS) imaging
have identified cortical gray matter volumes that decreased substantially
over time with proton MRS reflecting this finding with decreasing N-
acetyl aspartate (neuronal marker) and increasing myoinositol (gliosis
marker). Diffusion weighted imaging also has been evaluated to supple-
ment the clinical disability scale in an attempt to provide a quantitative
assessment of neurodegeneration. Although higher apparent diffusion
coefficients (ADC) were found in NCL-affected children compared to
age-matched controls, correlation with the degree of disability was not
statistically significant. The role of MRS and ADC in cats with NCL is
unknown. The general calvarial hyperostosis identified in both cats (our
cat and the previously reported cat12) is suspected to be a dynamic rela-
tionship in brain size and skull thickness.28
Both detected protein-changing variants in the MFSD8 gene were
in perfect linkage disequilibrium. Based on the available data, it there-
fore is impossible to make conclusive statements about the functional
relevance of the individual variants. The p.Asp7His missense variant
might be a functionally neutral variant that merely is in strong linkage
disequilibrium with the true causative variant. The c.780delT variant
causes a frameshift and thus most likely leads to a complete loss of
function of the MFSD8 gene. Given the known impact of MFSD8 vari-
ants in other species, it therefore seems highly probable that this vari-
ant is pathogenic and responsible for the NCL phenotype in the
affected cat. The genetic data strongly suggest that this case should
be classified as CLN7 because it is most likely due to a deficiency in
MFSD8.
In humans, 30 different genetic variants have been identified in
CLN7 comprising missense, nonsense, or deletion/frameshift variants
affecting protein function.29 Across species, genetic rodent models of
CLN7 have been created and spontaneous large animal models of
CLN7 have been reported in dogs (Chinese crested dogs19 and
Chihuahuas18,22) and non-human primates (Japanese macaques29).
When comparing neurological findings of our cat and the reported
NCL cats with the 2 aforementioned species, head tilt (dog and
macaque) and hypermetria (macaque) were never a feature in any of
the cats. Genetic variants of MFSD8 also were reported in human
patients with ocular disease (nonsyndromic macular dystrophy with
central cone involvement [CCMD]) without neurological features,
suggesting that NCL and CCMD are likely not different disease enti-
ties but rather allelic diseases.30
The main limitations of our study are the examination of a single
affected cat and the absence of histopathology. The established
importance of the MFSD8 gene as a cause of CLN7 in several other
species, the predicted effect of the variant, and the absence of the
mutant allele in the control cats all suggest that the frameshift variant
is pathogenic and the cause of the observed NCL in this cat.
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